Get to know our clinical trials
Trial of datopotamab deruxtecan in monotherapy and in combination with antineoplastic agents in patients with advanced or metastatic solid tumors.
WE ARE CONDUCTING THIS TRIAL TO LEARN MORE ABOUT THE DRUG DATOPOTOMAB-DERUXTECAN (DATO-DXD) WHEN USED ALONE (MONOTHERAPY) AND WHEN USED WITH OTHER ANTICANCER DRUGS (COMBINATION TREATMENT).
Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- PHASE II, MULTICENTER, OPEN-LABEL, MASTER PROTOCOL TO EVALUATE THE EFFICACY AND SAFETY OF DATOPOTAMAB DERUXTECAN (DATO-DXD) IN MONOTHERAPY AND IN COMBINATION WITH ANTINEOPLASTIC AGENTS IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS. IMMUNOTHERAPY
- Code EudraCT: -
- Protocol number: D926UC00001
- Promoter: Astra Zeneca AB
- Molecule/Drug: datopotamab deruxtecán (Dato-DXd)
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.